Analyst Price Target is $26.43
▲ +148.16% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for 89BIO in the last 3 months. The average price target is $26.43, with a high forecast of $49.00 and a low forecast of $11.00. The average price target represents a 148.16% upside from the last price of $10.65.
Current Consensus is
Buy
The current consensus among 8 polled investment analysts is to buy stock in 89BIO. This rating has held steady since April 2025, when it changed from a Moderate Buy consensus rating.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Read More